PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Growth of 153.33% while GNPX shows flat revenue. Bruce Berkowitz would examine growth quality advantage.
-27.15%
Cost reduction while GNPX shows 289.99% growth. Joel Greenblatt would examine competitive advantage.
73.30%
Positive growth while GNPX shows decline. John Neff would investigate competitive advantages.
89.46%
Margin change of 89.46% while GNPX shows flat margins. Bruce Berkowitz would examine quality advantage.
8.30%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
28.80%
G&A growth 50-75% of GNPX's 39.25%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth 1.25-1.5x GNPX's 11.64%. Martin Whitman would scrutinize control.
14.70%
Total costs growth 1.25-1.5x GNPX's 11.64%. Martin Whitman would scrutinize control.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-27.15%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-16.20%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
54.13%
Margin change of 54.13% while GNPX is flat. Bruce Berkowitz would examine quality.
-15.23%
Both companies show declining income. Martin Whitman would check industry conditions.
54.52%
Margin change of 54.52% while GNPX is flat. Bruce Berkowitz would examine quality.
98.15%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
-12.38%
Both companies show declining income. Martin Whitman would check industry conditions.
55.64%
Margin change of 55.64% while GNPX is flat. Bruce Berkowitz would examine quality.
-98.15%
Both companies reducing tax expense. Martin Whitman would check patterns.
-9.33%
Both companies show declining income. Martin Whitman would check industry conditions.
56.84%
Margin change of 56.84% while GNPX is flat. Bruce Berkowitz would examine quality.
-5.41%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-8.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.98%
Share count reduction below 50% of GNPX's 0.17%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of GNPX's 0.15%. Michael Burry would check for concerns.